The project addresses the need for improved toxicity assays for better risk assessment to reduce the number of animals used to test toxins and toxic effects. These assays will be developed as kits for commercial availability.
Prototype hiv vaccines consisting of dna vectors that express either single hiv genes or artificial genes consisting of several genes and gene fragments will be tested for safety, immunogenicity and therapeutic effect in clinical trials and for a therapeutic effect in an animal model.
To develop a robust point of care test for monitoring the effect of cancer therapy, based on antibodies directed to a patented peptide involved in cell proliferation.
To develop and validate an in-vitro test, the cytokine profile assay (cpa), with the purpose of improving presently available allergenicity test, and to substitute the use of animals for this type of testing.
Development of a rapid and easy-to-use anti-epo affinity tool for purifying epo from urine and blood which facilitates characterisation of epo isoforms appearing during pathological conditions and differentiation of endogenous and recombinant epo during therapy and after illegal doping.
Iron deficiency is the main cause of nutritional anaemias and is a world health problem. The objective is to obtain heme iron from animal haemoglobin in suitable administration form in order to conduct absorption studies with a target population.
To produce services and products for the rapid detection and identification of viruses in moroccan aquatic animals combining automatic image analysis of electron microscopy images and real-time rt-pcr. Success in this project is of great interest for the fish industry as a whole.
Development of candidate vaccine strains that can be used directly by industry in new cell-based production systems to manufacture influenza vaccines, and the development of a sublingual vaccination route for more efficient vaccination strategies.
To develop a novel medical sensor assembly for the in-vivo study of clinically important molecules. The sensor system will be developed to a stage where it is ready to become a commercial product.
The optimisation of the manufacturing process and the relevant probiotic bacteria strains to obtain a cleaner bacteria mix free from animal by-products, creating an innovative substance which will result in a new unique product with innovative application possibilities.